Brief: Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as Treatment to Prevent Acute Kidney Injury
27/02/2024 12:48
Feb 27 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS HAS PRE-IND MEETING WITH FDA TO DISCUSS
REPURPOSING CILASTATIN AS A NEW TREATMENT TO PREVENT ACUTE
KIDNEY INJURY
* ARCH BIOPARTNERS: MANAGEMENT DOES NOT HAVE PLANS TO RAISE
FUNDS
DURING 2024 IN CAPITAL MARKETS FOR CILASTATIN TRIALS
* ARCH BIOPARTNERS: ARRANGED FOR PRODUCTION OF FIRST LOT OF
CILASTATIN TO OCCUR DURING SUMMER OF 2024
Source text for Eikon: ID:nGNX3byHkC
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide